Healthcare stocks see mixed performance as Dr Lal Pathlabs and Aurobindo Pharma rise over 2% after CLSA upgrades their ...

CLSA analysts downgraded Dr. Reddy's Laboratories shares, trading on both BSE (DRRD:IN) and NYSE (NYSE:RDY), from a Hold to an Underperform rating, adjusting the price target from INR1,140 to INR1,090 ...

The firm expects mid-single-digit price erosion in generic drugs and heightened competition for key medications, potentially ...

Laurence Balanco, the CLSA chartist, expects the Nifty 50 index to slip to levels of 22,000, as it has broken below key support levels on Monday. In a note, Balanco said that the lack of follow ...

The brokerage firm has also added Zomato to its high conviction outperform list, saying the recent correction is a buying ...

Shares of Zomato surged as much as 7.27% to reach INR 261.75 during the intraday trading session on the BSE today (January 16 ...

This steady growth in HDFC Bank's core earnings - both NII and net profit - came in despite a marginal rise in NPAs and NPA ...

CLSA has included Zomato in its High Conviction Outperform list, maintaining an "Overweight" rating and increasing the target ...

CLSA believes the company must reduce its dependence on the Creta and introduce higher-priced SUVs in the Rs 20 Lakh+ segment ...

On Thursday, CLSA analysts downgraded Dr. Reddy's Laboratories shares, trading on both BSE (DRRD:IN) and NYSE (NYSE:RDY), from a Hold to an Underperform rating, adjusting the price target from ...

On Thursday, CLSA analysts downgraded Dr. Reddy's Laboratories shares, trading on both BSE (DRRD:IN) and NYSE (NYSE:RDY), from a Hold to an Underperform rating, adjusting the price target from ...